Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance

Gastroenterology

Volumn 125, Issue 1, 2003, Pages 80-88

  Gerlach, J Tilman ^a,b   Diepolder, Helmut M ^a   Zachoval, Reinhart ^a   Gruener, Norbert H ^a   Jung, Maria Christina ^a   Ulsenheimer, Axel ^a   Schraut, Winfried W ^a   Schirren, C Albrecht ^a   Waechtler, M ^a   Backmund, M ^a   Pape, Gerd R ^a  

^a Klinikum Schwabing   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HEPATITIS C ANTIBODY; RECOMBINANT ALPHA2 INTERFERON; RIBAVIRIN; VIRUS RNA;

ACUTE HEPATITIS; ADULT; ARTICLE; CHRONIC HEPATITIS; CLEARANCE; CLINICAL FEATURE; DISEASE COURSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT OUTCOME;

EID: 0038575483     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)00668-1     Document Type: Article

References (33)

1. Donahue JG, Munoz A, Ness PM, Brown DE Jr, Yawn DH, McAllister HA Jr, Reitz BA, Nelson KE. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992;327: 369-373.
2. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-562.
3. Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999;107:2S-9S.
4. Omata M, Yokosuka O, Takano S, Kato N, Hosoda K, Imazeki F, Tada M, Ito Y, Ohto M. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 1991;338:914-915.
5. Tassopoulos NC, Koutelou MG, Papatheodoridis G, Polychronaki H, Delladetsima I, Giannikakis T, Todoulos A, Toliopoulos A, Hatzakis A. Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis. Gut 1993;34:S130-S132.
6. Hwang SJ, Lee SD, Chan CY, Lu RH, Lo KJ. A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. J Hepatol 1994;21:831-836.
7. Lampertico P, Rumi, M, Romeo R, Craxi A, Soffredini R, Biassoni D, Colombo M. A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C. Hepatology 1994;19:19-22.
8. Viladomiu L, Genesca J, Esteban JI, Allende H, Gonzalez A, Lopez Talavera JC, Esteban R, Guardia J. Interferon-alpha in acute post-transfusion hepatitis C: a randomized, controlled trial. Hepatology 1992;15:767-769.
9. Ohnishi K, Nomura F, Nakano M. Interferon therapy for acute posttransfusion non-A, non-B hepatitis: response with respect to anti-hepatitis C virus antibody status. Am J Gastroenterol 1991; 86:1041-1049.
10. Takano S, Satomura Y, Omata M. Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Japan Acute Hepatitis Cooperative Study Group. Gastroenterology 1994;107:805-811.
11. Vogt M, Lang T, Frosner G, Klingler C, Sendl AF, Zeller A, Wiebecke B, Langer B, Meisner H, Hess J. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999;341:866-870.
12. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-1233.
13. Alter H, Seeff L. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000;20:17-35.
14. Busch U, Nitschko H. Methods for the differentiation of microorganisms. J Chromatogr B Biomed Sci Appl 1999;5:263-278.
15. Lemaire JM, Courouce AM, Defer C, Bouchardeau F, Coste J, Agulles O, Cantaloube JF, Barlet V, Barin F. HCV RNA in blood donors with isolated reactivities by third-generation RIBA. Transfusion 2000;40:867-870.
16. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672.
17. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343: 1673-1680.
18. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
19. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, Rumi MG, Houghton M, Fiaccadori F, Ferrari C. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996;98:706-714.
20. Gerlach JT, Diepolder HM, Jung M-C, Gruener NH, Schraut WW, Zachoval R, Hoffmann R, Schirren CA, Santantonio CA, Pape GR. Recurrence of hepatitis C virus after loss of virus-specific CD4+ T-cell response in acute hepatitis C. Gastroenterology 1999;117: 933-941.
21. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001;194:1395-1406.
22. Chang KM, Rehermann B, McHutchison JG, Pasquinelli C, Southwood S, Sette A, Chisari FV. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest 1997;100:2376-2385.
23. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, Chien DY, Munoz SJ, Balestrieri A, Purcell RH, Alter HJ. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000;288:339-344.
24. Tsai SL, Chen YM, Chen MH, Huang CY, Sheen IS, Yeh CT, Huang JH, Kuo GC, Liaw YF. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology 1998;115:954-965.
25. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC, Eichenlaub D, Pape GR. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346:1006-1007.
26. Missale G, Bertoni R, Valli A, Lamonaca V, Massari M, Berghenti F, Magnani G, Mori C, Fiaccadori F, Ferrari C. Hepatitis C virus (HCV) specific T cell response: long-term follow up after acute hepatitis C (abstr). J Hepatol 1995;23:126A.
27. Gruener NH, Gerlach JT, Jung M-C, Diepolder H, Schirren CA, Schraut W, Hoffmann R, Zachoval R, Santantonio T, Cucchiarini M, Cerny A, Pape GR. Association of hepatitis C virus specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis 2000;181:1528-1536.
28. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller J, Manns M, Rehermann B. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000;6:578-582.
29. Vogel W, Graziadei I, Umlauft F, Datz C, Hackl F, Allinger S, Grunewald K, Patsch J. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study. Dig Dis Sci 1996;41:81s-85s.
30. Camma C, Almasio P, Craxi A. Interferon as treatment for acute hepatitis C. A meta-analysis. Dig Dis Sci 1996;41:1248-1255.
31. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns MP. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452-1457.
32. Hoofnagle JH. Therapy for acute hepatitis C. N Engl J Med 2001; 345:1495-1497.
33. Piasecki BA, Reddy KR, Chang KM. Acute hepatitis C: to treat or not to treat? Hepatology 2002;35:1538-1540.